TrialBMJ open2023

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark.

Karen Brorup Heje Pedersen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.